Cytokinetics, Inc. (CYTK)

[H2R]

Some context for the recent PR

A year ago, SmithOnStocks published an assessment on CYTK. Here is a short excerpt on the Financial Position from Feb. 2016:

The Company ended 3Q, 2015 with $98 million of cash. The cash burn from operations has been running at about $10 million per quarter and if that rate held in 4Q, 2015 the Company currently has about $88 million of cash, CEO Robert Blum has said that the Company anticipates that it will receive $50 million in milestone payments from Amgen (for omecamtiv) and Astellas (for CK-2127107) over the next year or two. This effectively increases the availability of cash through the end of 2017 to $138 million.

At the recent quarterly burn rate of $10 million, this cash would last until mid-2018. However, the expense of the phase 3 trial of tirasemtiv should increase the burn. Management has given no guidance, but if the burn were to increase to $15 million per quarter, this $138 million of cash would last until early 2018 or well past the reporting of topline results from the phase 3 trial of tirasemtiv.

It looks like CYTK is keeping its coffers at a comfortable level for now. They do have a number of trials to fund!